12 March 2025 - NICE has published final evidence-based recommendations on the use of zolbetuximab (Vyloy) in combination with chemotherapy for the first-line treatment of adults with claudin-18.2 positive, HER2 negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma.

Zolbetuximab, when used in combination with fluoropyrimidine- and platinum-based chemotherapy, is not recommended for the first-line treatment of adults with locally advanced, unresectable or metastatic, claudin-18.2 positive, HER2 negative, gastric or gastro-oesophageal junction adenocarcinoma.

Read NICE technology appraisal guidance